Viewing Study NCT05590403

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:44 PM
Ignite Modification Date: 2026-04-14 @ 10:49 AM
Study NCT ID: NCT05590403
Status: COMPLETED
Last Update Posted: 2025-03-06
First Post: 2022-10-18
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Respiratory Syncytial Virus Infections View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Respiratory syncytial virus View
None Immunogenicity View
None Safety View
None Increased risk of respiratory syncytial virus lower respiratory tract disease View
None Adults aged 50-59 years of age View
None Older adults 60 years of age and above View